140 related articles for article (PubMed ID: 8109926)
1. Pharmacodynamic activity of a cephalosporin, Ro 40-6890, in human skin blister fluid: antibiotic activity in concert with host defense mechanisms.
Hoogkamer JF; Hesse WH; Sansano S; Zimmerli W
Antimicrob Agents Chemother; 1993 Dec; 37(12):2622-7. PubMed ID: 8109926
[TBL] [Abstract][Full Text] [Related]
2. Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788.
Drugs R D; 2006; 7(5):305-11. PubMed ID: 16922591
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid.
Kalman D; Barriere SL; Johnson BL
Antimicrob Agents Chemother; 1992 Feb; 36(2):453-7. PubMed ID: 1605609
[TBL] [Abstract][Full Text] [Related]
4. [Skin penetration of sulfamethoxazole and trimethoprim after oral administration].
Królicki A
Ann Acad Med Stetin; 2002; 48():59-73. PubMed ID: 14601469
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of cefetamet in plasma and skin blister fluid.
Zimmerli W; Sansano S; Wittke B
Antimicrob Agents Chemother; 1996 Jan; 40(1):102-4. PubMed ID: 8787888
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a granulocyte-rich exudate.
Trampuz A; Laifer G; Wenk M; Rajacic Z; Zimmerli W
Antimicrob Agents Chemother; 2002 Nov; 46(11):3630-3. PubMed ID: 12384378
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid.
Trampuz A; Wenk M; Rajacic Z; Zimmerli W
Antimicrob Agents Chemother; 2000 May; 44(5):1352-5. PubMed ID: 10770776
[TBL] [Abstract][Full Text] [Related]
8. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis.
Entenza JM; Hohl P; Heinze-Krauss I; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 2002 Jan; 46(1):171-7. PubMed ID: 11751129
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of dalbavancin in plasma and skin blister fluid.
Nicolau DP; Sun HK; Seltzer E; Buckwalter M; Dowell JA
J Antimicrob Chemother; 2007 Sep; 60(3):681-4. PubMed ID: 17631507
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
11. Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model.
Palmer SM; Kang SL; Cappelletty DM; Rybak MJ
Antimicrob Agents Chemother; 1995 Aug; 39(8):1764-71. PubMed ID: 7486916
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci.
Hebeisen P; Heinze-Krauss I; Angehrn P; Hohl P; Page MG; Then RL
Antimicrob Agents Chemother; 2001 Mar; 45(3):825-36. PubMed ID: 11181368
[TBL] [Abstract][Full Text] [Related]
13. Penetration of antibiotics into human leukocytes and dermal suction blisters.
Solberg CO; Halstensen A; Digranes A; Hellum KB
Rev Infect Dis; 1983; 5 Suppl 3():S468-73. PubMed ID: 6635436
[TBL] [Abstract][Full Text] [Related]
14. Plasma and skin blister fluid concentrations of metronidazole and its hydroxy metabolite after oral administration.
Klimowicz A; Nowak A; Bielecka-Grzela S
Pol J Pharmacol; 1996; 48(1):47-52. PubMed ID: 9112627
[TBL] [Abstract][Full Text] [Related]
15. Human plasma and skin blister fluid levels of griseofulvin following a single oral dose.
Schäfer-Korting M; Korting HC; Mutschler E
Eur J Clin Pharmacol; 1985; 29(1):109-13. PubMed ID: 4054199
[TBL] [Abstract][Full Text] [Related]
16. Evaluation in an animal model and in vitro of the combination clavulanic acid and cephalosporins against beta-lactamase producing and nonproducing Staphylococcus aureus strains.
de Sá Del Fiol F; Rocha De Mattos Filho T; Groppo FC
Braz J Infect Dis; 2000 Feb; 4(1):36-42. PubMed ID: 10788844
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of cefovecin in dogs.
Stegemann MR; Sherington J; Blanchflower S
J Vet Pharmacol Ther; 2006 Dec; 29(6):501-11. PubMed ID: 17083454
[TBL] [Abstract][Full Text] [Related]
18. Failure of time-kill synergy studies using subinhibitory antimicrobial concentrations to predict in vivo antagonism of cephalosporin-rifampin combinations against Staphylococcus aureus.
Brandt CM; Rouse MS; Tallan BM; Wilson WR; Steckelberg JM
Antimicrob Agents Chemother; 1994 Sep; 38(9):2191-3. PubMed ID: 7811044
[TBL] [Abstract][Full Text] [Related]
19. Correlation of in-vitro parameters of antimicrobial activity with prophylactic efficacy in an intradermal model of Staphylococcus aureus infection.
Warren MD; Kernodle DS; Kaiser AB
J Antimicrob Chemother; 1991 Nov; 28(5):731-40. PubMed ID: 1778876
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity and disk diffusion susceptibility testing of Ro 40-6890, the active metabolite of the new cephalosporin ester, Ro 41-3399.
Pfaller MA; Barry AL; Fuchs PC
Antimicrob Agents Chemother; 1993 Apr; 37(4):893-5. PubMed ID: 8494387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
